# US 2012/0251619 A1 · MicroRNA-29a,b,c as a Tumor Suppressor and Sensitizing Agent for Chemotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251619 A1
- Document ID: US20120251619A1
- Status: Published application
- Kind: A1
- Application number: 13/437,128
- Filed: 2012-04-02
- Published: 2012-10-04
- Earliest claimed: 2011-03-31
- Inventors: Preethi H. Gunaratne
- Web page: https://patentgrep.com/patent/US20120251619A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 33/243: Platinum; Compounds thereof
- A61P 35/00: Antineoplastic agents
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61N 2005/1098: {Enhancing the effect of the particle by an injected agent or implanted device}
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)

## Abstract

The present invention provides a method of improving a therapeutic response to a cancer treatment, in a subject, the method comprising administering an effective amount of an agent that enhances the expression of microRNA 29 or an agent that mimics the effects of microRNA 29. Further provided is a method of treating a cancer in a subject in need of such treatment comprising the step of administering an effective amount of a microRNA 29 or an agent that enhances the expression of microRNA 29.

## Claims

### Claim 1

A method of providing a prognosis for ovarian cancer in a subject, comprising the steps of:
obtaining a biological sample from said subject; and
testing said biological sample to determine whether or not microRNA 29 is under-expressed in said sample, relative to the expression of microRNA 29 in a control sample, whereby the under-expression of microRNA 29 in said biological sample indicates that a tumor in said subject is resistant to a chemotherapy.

### Claim 2

A method of improving a therapeutic response to a cancer treatment, in a subject, the method comprising administering an effective amount of an agent that enhances the expression of microRNA 29 or an agent that mimics the effects of microRNA 29.

### Claim 3 (depends on 2)

The method of claim 2, whereby said agent is microRNA 29a, microRNA 29b or microRNA 29c.

### Claim 4 (depends on 2)

The method of claim 2, whereby said agent is a double-stranded miRNA mimic.

### Claim 5 (depends on 2)

The method of claim 2, whereby said agent is an oligonucleotide based pre-microRNA 29 drug.

### Claim 6 (depends on 2)

The method of claim 2, whereby said cancer is selected from the group consisting of lung cancer, pancreatic cancer, skin cancer, hematological neoplasms, breast cancer, brain cancer, colon cancer, follicular lymphoma, bladder cancer, cervical cancer, endometrial cancer, esophageal cancer, gastric cancer, head and neck cancer, multiple myeloma, liver cancer, lymphomas, oral cancer, osteosarcomas, ovarian cancer, uterine leiomyosarcoma, uterine leiomyomas, endometriomas, endometriosis, uterine papillary serous carcinomas, prostate cancer, testicular cancer and thyroid cancer.

### Claim 7 (depends on 6)

The method of claim 6, whereby said cancer is epithelial ovarian cancer.

### Claim 8 (depends on 2)

The method of claim 2, whereby said therapeutic response comprises treating with radiation, carboplatin, cisplatin, paclitaxel, an alkylating agent, an antimetabolite, an antitumor antibiotic and a DNA topoisomerase inhibitor.

### Claim 9

A kit for determining a chemotherapy response in a patient with a cancer, said kit comprising: a) a oligonucleotide complementary to microRNA 29; and b) optionally, reagents for the formation of the hybridization between said oligonucleotide and said microRNA 29.

### Claim 10 (depends on 9)

The kit according to claim 9, wherein said microRNA 29 is detectably labeled.

### Claim 11 (depends on 9)

The kit according to claim 9, wherein said microRNA 29 is attached to a solid surface.

### Claim 12 (depends on 9)

The kit according to claim 9, wherein said microRNA 29 is a member of a nucleic acid array.

### Claim 13 (depends on 12)

The kit according to claim 12, wherein said nucleic acid array is a microarray.

### Claim 14

A pharmaceutical composition for improving a tumor response to chemotherapy, said composition comprising an effective amount of microRNA 29 or an agent that enhances the expression of microRNA 29.

### Claim 15

A method of treating a cancer in a subject in need of such treatment comprising the step of administering an effective amount of a microRNA 29 or an agent that enhances the expression of microRNA 29.

### Claim 16 (depends on 15)

The method of claim 15, whereby said agent is microRNA 29a, microRNA 29b or microRNA 29c.

### Claim 17 (depends on 15)

The method of claim 15, whereby said agent is a double-stranded miRNA mimic.

### Claim 18 (depends on 15)

The method of claim 15, whereby said agent is an oligonucleotide based pre-microRNA 29 drug.

### Claim 19 (depends on 15)

The method of claim 15, whereby said cancer is selected from the group consisting of lung cancer, pancreatic cancer, skin cancer, hematological neoplasms, breast cancer, brain cancer, colon cancer, follicular lymphoma, bladder cancer, cervical cancer, endometrial cancer, esophageal cancer, gastric cancer, head and neck cancer, multiple myeloma, liver cancer, lymphomas, oral cancer, osteosarcomas, ovarian cancer, uterine leiomyosarcoma, uterine leiomyomas, endometriomas, endometriosis, uterine papillary serous carcinomas, prostate cancer, testicular cancer and thyroid cancer.

### Claim 20 (depends on 19)

The method of claim 19, whereby said cancer is epithelial ovarian cancer.

### Claim 21 (depends on 15)

The method of claim 15, further comprising:
treating said subject with radiation, carboplatin, cisplatin, paclitaxel, an alkylating agent, an antimetabolite, an antitumor antibiotic and a DNA topoisomerase inhibitor.

### Claim 22 (depends on 15)

The method of claim 15, wherein said microRNA 29 is administered as a nucleic acid construct encoding an artificial miRNA presented as a double-stranded RNA, a precursor hairpin, a primary miRNA in single straded RNA form or encoded in a DNA vector delivered in a suitable pharmaceutical carrier.

### Claim 23 (depends on 22)

The method of claim 22, wherein said pharmaceutical carrier is selected from the group consisting of a virus, a liposome, and a polymer.

### Claim 24 (depends on 15)

The method of claim 15, wherein said microRNA 29 is administered as a nanoparticle, a liposome, a vector or a polymer.

### Claim 25 (depends on 24)

The method of claim 24, wherein said vector selected from the group consisting of a plasmid, a cosmid, a phagemid and a virus.
